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survival analyses (Kaplan Meier log-rank test) were con-
ducted to investigate factors affecting disease-free survival
(DFS) and overall survival (OS). Group differences between
cases with/without GVHD were examined by t-tests on
engraftment lab variables.
The median age was 44 years (20-70). AML/MDS
accounted for 71% of the cases. Indications for second
alloHSCT were graft failure (16%) and disease relapse
(84%). Myeloablative conditioning was used in 62% of
the patients. Median time from ﬁrst to second trans-
plant was 427 days (49-3835) and median time from
relapse to second alloHSCT was 142 days (16-2524). 62%
of the second alloHSCTs were from an unrelated donor.
36% of second transplants were from the original donor.
OS at 1 and 5 years was 41% and 21% respectively
[median 229 days (5 e 5320)]. Factors prolonging OS
were: GVHD (P ¼ .05), chronic GVHD (cGVHD) (P < .01)
and using the same donor for both alloHSCTs (P < .01).
Male recipients, transplant from females to males, and
transplants from unrelated donors trended towards
better survival rates but were not signiﬁcant (P ¼ .069,
0.09, and 0.059 respectively). Survival was not affected
by: age, acute GVHD (aGVHD), diagnosis, risk stratiﬁca-
tion at diagnosis or second alloHSCT, remission status at
second alloHSCT, conditioning intensity, HLA compati-
bility, donor's sex, or CMV status of the donor/recipient.
The median DFS after the second alloHSCT was 112 days
(5-4759). Incidence of aGVHD and cGVHD was 41% and
41% respectively. Patients who developed GVHD or
cGVHD had better DFS (P < .01, P ¼ .03, respectively).
Risk of GVHD was higher in patients who received more
CD34/kg cells (P ¼ .02) while CD3/kg dose was not
statistically signiﬁcant. Remission status at the time of
the second alloHSCT did not affect OS or DFS. 13% of the
patients developed CMV viremia. Median time to
neutrophil engraftment was 12 days (4-37), and median
platelet engraftment >50,000/mcL was 21 days (9-103).
Patients who developed GVHD had earlier platelet
engraftment (Means: 16 vs. 30 days, P ¼ .04).
This single center experience of second alloHSCT suggests
this treatment results in long-term survival in select patients.
Survival is improved when the original donor is used as the
second donor. Future studies will focus on predictive
modeling to help choose patients who may beneﬁt most
from a second alloHSCT.403
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Graft failure is a well described complication of allogeneic
hematopoietic cell transplantation (HCT). The likelihood of
graft failure is greater when an HLA-mismatched donor
(such as umbilical cord blood or haploidentical donor) is
utilized. Salvage transplantations are associated with high
mortality because of common concurrent infections and
poor tolerance to reconditioning. We describe the use of
a novel reduced-intensity regimen that combines four potent
immunosuppressive but well tolerated agents with non-
overlapping toxicities.
Patients received 8 Gy TLI divided 2 Gy per fraction (once
daily on days -10, -9, and twice daily on day -8). Fludarabine
at 40mg/m2/day on the following 3 days (-7, -6, and -5).
Cyclophosphamide at 50mg/kg/day over 3 days (-4, -3, -2).
Rabbit ATG at 1mg/kg on day -3, and then 3mg/kg/day on
days -2 and -1. Patients then received a CliniMacs T-cell
depleted peripheral blood stem cell graft from a hap-
loidentical donor. The patients were typically heavily pre-
treated, had prolonged neutropenia, andmany had identiﬁed
infections.
In total, 7 patients experienced graft failure after hap-
loidentical donor HCT (3 had primary graft failure; 4 had
brief engraftment with subsequent rejection). They received
salvage HCT at a median of 37 days (range 31 e 78 days)
following the ﬁrst HCT (with the same haploidentical donor
in 5 and an alternative haploidentical donor in 2 recipients).
Patient 7 required modiﬁcation of the regimen (no cyclo-
phosphamide given) due to ongoing mechanical ventilation
and pressor support. Six of the 7 patients (86%) experienced
durable engraftment beginning at amedian of 12 days (range
10 e 27 days). All 6 were successfully discharged from the
hospital post-engraftment including Patient 7. The remain-
ing patient had rapidly progressive disease and never had
signs of engraftment before death at day 101 after the salvage
HCT. No other patient has relapsed. Patient 7 ultimately
expired due to CMV pneumonitis at 103 days after salvage
HCT. The remaining ﬁve patients are alive at a median of 846
days after salvage HCT (range 131 to 2569 days). Two patients
had acute and 3 had chronic GvHD; all resolved.
Our results indicate that this novel immunosuppressive
regimen is tolerable and effective in this heavily pretreated
patient population. High success rate in reengraftment was
observed despite the use of T-cell depleted haploidentical
grafts, including those from the same donor whose graft was
previously rejected.ays) 2nd Donor Time to Neutrophil Engraftment (days) Outcome
Mother 27 Alive
Mother 11 Alive
Mother na Expired (ALL)
Mother 11 Alive
Mother 14 Alive
Father 10 Alive
Father 13 Expired (CMV)
